Tooba Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 12-12-2024
- Paid Up Capital ₹ 2.44 Cr
as on 12-12-2024
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.10 M
as on 12-12-2024
- Revenue 97.24%
(FY 2022)
- Profit 14.35%
(FY 2022)
- Ebitda 27.51%
(FY 2022)
- Net Worth 1.38%
(FY 2022)
- Total Assets 2.40%
(FY 2022)
About Tooba Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.44 Cr.
The company currently has active open charges totaling ₹0.10 M.
Rizwana Khanum and Mohammed Siddiqui serve as directors at the Company.
- CIN/LLPIN
U51397MH2008PTC183817
- Company No.
183817
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Tooba Pharmaceuticals Private Limited offer?
Tooba Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients).
Who are the key members and board of directors at Tooba Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rizwana Khanum  | Director | 21-Jun-2008 | Current |
| Mohammed Siddiqui | Director | 21-Jun-2008 | Current |
Financial Performance of Tooba Pharmaceuticals.
Tooba Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 97.24% increase. The company also saw a substantial improvement in profitability, with a 14.35% increase in profit. The company's net worth moved up by a moderate rise of 1.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tooba Pharmaceuticals?
In 2022, Tooba Pharmaceuticals had a public holding of 32.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Tooba Global Pharmaceutical Private LimitedActive 2 months 22 daysMohammed Siddiqui is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bombay Mercantile Co-Operative Bank Ltd Creation Date: 12 Aug 2014 | ₹0.10 M | Open |
How Many Employees Work at Tooba Pharmaceuticals?
Unlock and access historical data on people associated with Tooba Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tooba Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tooba Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
